Milton Packer

7 ta ish

Baylor Jack and Jane Hamilton Heart and Vascular Hospital

1. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

   Milton Packer, Stefan D. Anker, Javed Butler +36

   Maqola20208 iqtibos

   ABIABI:AkademIndex/2026.other.282518

2. Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure

   John J.V. McMurray, Milton Packer, Akshay S. Desai +8

   Maqola20146 iqtibos

   ABIABI:AkademIndex/2026.other.295755

3. Critical Reanalysis of the Mechanisms Underlying the Cardiorenal Benefits of SGLT2 Inhibitors and Reaffirmation of the Nutrient Deprivation Signaling/Autophagy Hypothesis

   Milton Packer

   Sharh maqola20222 iqtibos

   ABIABI:AkademIndex/2026.other.282548

4. The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure

   Milton Packer, Michael R. Bristow, Jay N. Cohn +4

   Maqola19962 iqtibos

   ABIABI:AkademIndex/2026.other.295804

5. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials

   John G.F. Cleland, Karina V Bunting, Marcus Flather +19

   Sharh maqola20172 iqtibos

   ABIABI:AkademIndex/2026.other.295838

6. Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction

   Scott D. Solomon, John J.V. McMurray, Inder S. Anand +31

   Maqola20192 iqtibos

   ABIABI:AkademIndex/2026.other.295865

7. Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure

   Scott D. Solomon, Muthiah Vaduganathan, Brian Claggett +22

   Maqola20192 iqtibos

   ABIABI:AkademIndex/2026.other.295867